-
The first Alzheimer's disease vaccine entered clinical trials in 20 years
Time of Update: 2021-12-06
ArticleMedicine GuanlanUS time on November 16, news, Brigham and Women's Hospital (Brigham and Women's Hospital) announced that it will start a phase 1 clinical trial to evaluate a new nasal vaccine in preventing and slowing the progression of Alzheimer's disease (AD) The safety and effectiveness .
-
A wave of mergers and acquisitions is emerging in the medical device industry, and industry giants will be strong in the future.
Time of Update: 2021-12-06
The first is the emergence of a large number of medical device companies, which has intensified competition in the entire industry, and mergers and acquisitions can accelerate the competitiveness of some of them and seize high-potential market segments .
-
Hillhouse adjusted its positions substantially in the third quarter, and the first three warehouses were all biopharmaceutical companies
Time of Update: 2021-12-06
In the third quarter of this year, BeiGene is still a major position in Hillhouse's US stocks .
In the F13 documents for the third quarter, BeiGene became a major position in Hillhouse's stock holdings, holding 5,472,300 shares, corresponding to a market value of US$1.
-
Tap into the overseas PD-1/L1 monoclonal antibody market Livzon Group "follows the trend" and enters the game
Time of Update: 2021-12-06
According to the agreement, Livzumab will license the recombinant humanized anti-PD-1 monoclonal antibody for injection (LZM009) with independent intellectual property rights (LZM009) to BPTx for a paid and non-exclusive license for the development of new PD-1 targeted immune cytokines (PD- 1 ICs), while authorizing LZM009 to BPTx for the development and commercialization of PD-1 ICs drugs in regions other than Greater China .
-
Industry: In the next 5 to 10 years, the level of China's medical equipment may be equal to that of Europe
Time of Update: 2021-12-06
In addition, in the past, China's medical equipment industry lacked some reasonable and stable incentive policies for the research and development of domestic equipment.
In addition, relevant and continuous incentive policies are also needed to encourage and support domestic pharmaceutical equipment companies to in-depth research and develop original products .
-
FDA delays Bristol-Myers Squibb's first-in-class cardiomyopathy drug listing application
Time of Update: 2021-12-06
The Phase III clinical results, code-named EXPLORER-HCM, showed that compared with the placebo group, Mavacamten showed clinically significant improvements in symptoms, functional status and quality of life in patients with symptomatic oHCM, reaching all primary and secondary clinical endpoints .
-
The second domestically produced generic drug!
Time of Update: 2021-12-06
It is reported that Hausen Pharmaceutical's fulvestrant is the second generic fulvestrant that was declared and approved by a Chinese company .
Now, after Tianqing, Hausen Pharmaceutical's fulvestrant has become the second domestic generic drug .
-
Many children's drug registration certificates have been cancelled!
Time of Update: 2021-12-06
For example, in China, in recent years, as the issue of children's medication has become a livelihood issue that the country attaches great importance to, in order to increase the research and development enthusiasm of manufacturers, the State Food and Drug Administration, the National Health Commission, and the Medical Insurance Bureau have successively introduced a series of policy measures.
-
Anti-CD40L antibody submitted clinical application in China for the treatment of systemic lupus erythematosus
Time of Update: 2021-12-06
Retrieved Nov 18, 2021, from https:// Efficacy and Safety of Dapirolizumab Pegol in Patients with Moderately to Severely Active Systemic Lupus Erythematosus: A Randomized, Placebo-Controlled Study.
org/abstract/efficacy-and-safety-of-dapirolizumab-pegol -in-patients-with-moderately-to-severely-active-systemic-lupus-erythematosus-a-randomized-placebo-controlled-study/
-
Comprehensive layout, multi-point blossom, new diabetes drug research and development, domestic pharmaceutical companies continue to appear
Time of Update: 2021-12-06
In recent years, Chinese pharmaceutical companies have gradually appeared in the research and development queue of new diabetes drugs, including Shanghai Renhui Biopharmaceuticals, Hausen Pharmaceuticals, Microchip Biopharmaceuticals, Hengrui Pharmaceuticals, Hualing Pharmaceuticals, Tonghua Dongbao, East China Pharmaceuticals, Ganli Pharmaceuticals, etc.
-
Diabetes digital management problems need to be solved urgently, and pharmaceutical companies are actively exploring and trying
Time of Update: 2021-12-06
Diabetes, as one of the four chronic diseases that the "Healthy China Action (2019-2030)" focuses on prevention and control, has become an important chronic disease threatening human health . Accor
-
The flow of talents in the pharmaceutical market accelerates the current senior management changes of more than 200 pharmaceutical companies during the year
Time of Update: 2021-12-06
More than 10 companies including Hengrui Pharmaceutical, Lexin Medical, Wantai Bio, Kanghong Pharmaceutical, and Ruizhi Pharmaceutical have issued announcements on the resignation of senior executives .
-
The domestic innovative drug track is becoming more and more "involved", what should pharmaceutical companies do?
Time of Update: 2021-12-06
Some popular tracks such as ADC drugs and PD-1 products are becoming more and more "involved", more and more companies are entering the game, and the amount of fundraising and financing is also increasing, and the competition is fierce .
-
my country's orthopedic equipment market has a bright future, and it is expected to exceed 50 billion yuan in 2023
Time of Update: 2021-12-06
At present, driven by multiple factors such as the continuous promotion of favorable policies and the continuous advancement of science and technology, the market capacity of orthopedic medical equipment in China is showing a trend of continuous expansion .
Among them, the orthopedic implant market scale was 36 billion yuan, a year-on-year increase of 16.
-
Over 300 million people in my country have sleep disorders, and the market for sleep aids is promising
Time of Update: 2021-12-06
Recently, China Galaxy Securities pointed out in its research report that the growth of sleep aid products for medical and health care products can be expected .
The penetration rate of medical and health products in the sleep economy of Chinese people is relatively low, accounting for only about 20%.
-
New crown drug made in China?
Time of Update: 2021-12-06
At the same time, there are few small molecule CDMO companies that can meet the production capacity of Pfizer's new crown drug, and Kailaiying is one of them .
-
Sichuan Province issued an important notice, the purchase of oral consumables with quantity or started
Time of Update: 2021-12-06
At present, the Sichuan Pharmaceutical Equipment Bidding and Purchasing Service Center has officially started the information declaration work for the maintenance of dental implants and repair abutment medical consumables.
-
Lupeng Pharmaceuticals completes the first subject administration of the new class 1 hepatitis B drug LP-128
Time of Update: 2021-12-06
Further, inhibitors and nucleoside of HBsAg (acid) in combination with anti-HBV drugs, is expected to substantially improve the cure rate of hepatitis .
It is expected to bring better treatment options and hope of cure for hepatitis B patients worldwide .
-
"Star drug" "Engliflozin" new indications for marketing application accepted
Time of Update: 2021-12-06
On September 30 this year, Eli Lilly issued a press release stating that it had submitted an application to CDE for the registration of new indications for adult patients with heart failure with enpagliflozin for ejection fraction preservation .
-
The R&D investment of local pharmaceutical companies is still "in full swing", and multinational pharmaceutical companies are also "heating up"
Time of Update: 2021-12-06
" Over 80% of the A-share listed pharmaceutical companies had increased their total R&D investment in the first three quarters compared with the same period last year .
